Most importantly, treatment with LG ameliorated DXM-induced NAFLD, and abrogated DXM-induced dysregulation of FASN, CD36, liver enzymes, and lipid profile. The gene discussed is FASN; the disease is metabolic dysfunction-associated steatotic liver disease.